



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1430
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO. 10/594,832	FIRST NAMED APPLICANT Changlu Liu	ATTY. DOCKET NO. PRD2203USPCT
INTERNATIONAL APPLICATION NO. PCT/US05/10279		
I.A. FILING DATE 03/29/2005		PRIORITY DATE 03/29/2004


27777
PHILIP S. JOHNSON
JOHNSON & JOHNSON
ONE JOHNSON & JOHNSON PLAZA
NEW BRUNSWICK, NJ 08933-7003

RECEIVED

MAY 16 2007

CONFIRMATION NO. 8383

J&J PAT. DKT. SECTION 371 FORMALITIES LETTER



Date Mailed: 05/14/2007

NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371 IN THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US)

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as a Designated / Elected Office (37 CFR 1.495).

- Copy of the International Application filed on 09/28/2006
- Oath or Declaration filed on 09/28/2006
- Biochemical Sequence Listing filed on 09/28/2006
- Request for Immediate Examination filed on 09/28/2006
- U.S. Basic National Fees filed on 09/28/2006
- Priority Documents filed on 09/28/2006

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

ALL OF THE ITEMS SET FORTH ABOVE MUST BE SUBMITTED WITHIN TWO (2) MONTHS FROM THE DATE OF THIS NOTICE OR BY 32 MONTHS FROM THE PRIORITY DATE FOR THE APPLICATION, WHICHEVER IS LATER. FAILURE TO PROPERLY RESPOND WILL RESULT IN ABANDONMENT.

The time period set above may be extended by filing a petition and fee for extension of time under the provisions of 37 CFR 1.136(a).

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- **For Rules Interpretation, call (571) 272-0951**
- **For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.**
- **Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov**

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

Registered users of EFS-Web may alternatively submit their reply to this notice via EFS-Web.
<https://portal.uspto.gov/authenticate/AuthenticateUserLocalEPF.html>

For more information about EFS-Web please call the USPTO Electronic Business Center at 1-866-217-9197 or visit our website at <http://www.uspto.gov/ebc>.

If you are not using EFS-Web to submit your reply, you must include a copy of this notice.

VIRGINIA L IRBY

Telephone: (703) 308-9140 EXT 229

PART 1 - ATTORNEY/APPLICANT COPY


U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/594,832	PCT/US05/10279	PRD2203USPCT



PCT/FW

Certificate of Mailing:

The undersigned certifies that this correspondence is being sent via first-class mail, with adequate postage, in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, this 13th day of July 2007.

(s) 
Helen J. Glenister

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Patent Applicant: Liu et al. Atty Docket No.: PRD2203USPCT
Serial No.: 10/594,832 Art Unit: unknown
I.A. Filing Date: March 29, 2005 Examiner: unknown
For: Prokineticin 2Beta Peptide And Confirmation No.: 8383
Its Use

Mail Stop Missing Parts
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RESPONSE TO NOTIFICATION OF MISSING REQUIREMENTS UNDER 35 U.S.C. 371
IN THE UNITED STATES DESIGNATED/ELECTED OFFICE

Sir:

This is a response to the Notification of Missing Requirements Under 35 U.S.C. 371 In The United States Designated/Elected Office (DO/EO/US) dated May 15, 2007 issued in the above-referenced national phase application. A copy of the Notice accompanies this response.

A Declaration And Power Of Attorney form bearing the signatures of the inventors is enclosed.

Additionally, as required by the Notice and in accordance with 37 C.F.R. § 1.821(e), enclosed is a diskette containing a computer readable form (CRF) of the paper copy of the Sequence Listing as filed on 29 March 2005, and 14 June 2006, in the international application, which published as WO 2005/097826. The content of the Sequence Listing information recorded in the enclosed CRF is identical to the written Sequence Listing of the original paper submission and thus includes no new matter.

If any other fees are necessary for the filing of this paper, please charge such required fees to Deposit Account No. 10-0750.

In view of the foregoing, the requirements set forth in the Notice have been met. Accordingly, Applicant requests prompt examination on the merits.

Respectfully submitted,

Date: July 13, 2007



Linda S. Evans
Reg. No. 33,873

Johnson & Johnson
One Johnson & Johnson Plaza
New Brunswick, New Jersey 08933-7003
(858) 320-3406